skip to main content


To date, SFX-01 has been administered to circa 200 patients and demonstrated a good safety and  tolerability profile.

Evgen has a clinical development programme ongoing in metastatic breast cancer (Phase II).  In addition, it is expected that a Phase II trial in glioma will be started in 2022.

The Company has started the preparatory work to file an IND around the end of 2021 to enable clinical studies to be conducted in the United States.